Y.S.P. Southeast Asia Holding

YSPSAH

MYL7178OO006

Pharmaceuticals

End-of-day quote BURSA MALAYSIA Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
2.9 ^MYR	-1.36%		+13.73%	+26.09%

May. 23	YSP Southeast Asia's Q1 Profit Rises on Improved Revenue	MT
Apr. 22	Y.S.P. Southeast Asia Holding Berhad Announces Final Single-Tier Special Dividend for the Financial Year Ended 31 December 2023, Payable on 22 July 2024	CI

Y.S.P. Southeast Asia Holding Berhad Appoints Puan Hasnah Binti Ismail as Independent and Non Executive Member of Remuneration Committee

March 20, 2023 at 08:37 am EDT

Y.S.P. Southeast Asia Holding Berhad announced appointment of Puan Hasnah Binti Ismail as Independent and Non Executive Member of Remuneration Committee. Date of change is March 20, 2023. Age is 70.

Composition of Remuneration Committee(Name and Directorate of members after change): Chairman: Mr. Chin Chew Mun (Independent Non-Executive Director). Members: Mr. Tu Shu Yao (Independent Non-Executive Director); Mr. Yau Teck Kong (Independent Non-Executive Director); and Pn. Hasnah binti Ismail (Independent Non-Executive Director).

Latest news about Y.S.P. Southeast Asia Holding

YSP Southeast Asia's Q1 Profit Rises on Improved Revenue	May. 23	MT
Y.S.P. Southeast Asia Holding Berhad Announces Final Single-Tier Special Dividend for the Financial Year Ended 31 December 2023, Payable on 22 July 2024	Apr. 22	CI
Y.S.P. Southeast Asia Holding Berhad Announces Final Single-Tier Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable on 22 Jul 2024	Apr. 22	CI
Y.S.P. Southeast Asia Holding Bhd. Proposes First and Final Single-Tier Ordinary Dividend in Respect of Financial Year Ended 31 December 2023	Mar. 20	CI
Y.S.P. Southeast Asia Holding Bhd. Proposes Special Dividend in Respect of Financial Year Ended 31 December 2023	Mar. 20	CI
Y.S.P. Southeast Asia Holding Berhad Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
YSP Southeast Asia's Profit Plunges in Q3	Nov. 22	MT
Y.S.P. Southeast Asia Holding Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21	CI
Y.S.P. Southeast Asia Holding Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Y.S.P. Southeast Asia Holding Berhad Announces Appointment of Mr. Lee Sen Huei as Independent and Non Executive Director	23-06-01	CI
Y.S.P. Southeast Asia Holding Berhad Announces Retirement of Dr. Lee Fang Chuan @ Lee Fang Chen as Non Independent and Non Executive Director	23-05-23	CI
Y.S.P. Southeast Asia Holding Berhad Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Y.S.P. Southeast Asia Holding Berhad Announces Final Single-Tier Special Dividend for the Financial Year Ended December 31, 2022, Payable on 25, 2023	23-04-25	CI
Y.S.P. Southeast Asia Holding Berhad Announces Final Single-Tier Ordinary Dividend for the Financial Year Ended December 31, 2022, Payable on July 25, 2023	23-04-25	CI
Y.S.P. Southeast Asia Holding Berhad Announces Resignation of Tu Shu Yao as Independent and Non Executive Director	23-03-31	CI
Y.S.P. Southeast Asia Holding Berhad Announces Re-Designation of Yau Teck Kong to Independent and Non Executive Chairman of Nomination Committee	23-03-31	CI
Y.S.P. Southeast Asia Holding Berhad Announces Resignation of Tu Shu Yao as Independent and Non Executive Member of Remuneration Committee	23-03-31	CI
Y.S.P. Southeast Asia Holding Berhad Announces Resignation of Tu Shu Yao as Independent and Non Executive Chairman of Nomination Committee	23-03-31	CI
Y.S.P. Southeast Asia Holding Berhad Announces Resignation of Tu Shu Yao as Independent and Non Executive Member of Audit Committee	23-03-31	CI
Y.S.P. Southeast Asia Holding Berhad Proposes Special Dividend for the Financial Year Ended 31 December 2022	23-03-20	CI
Y.S.P. Southeast Asia Holding Berhad Proposes First and Final Single-Tier Ordinary Dividend for the Financial Year Ended 31 December 2022	23-03-20	CI
Y.S.P. Southeast Asia Holding Berhad Appoints Puan Hasnah Binti Ismail as Independent and Non Executive Member of Remuneration Committee	23-03-20	CI
Y.S.P. Southeast Asia Holding Berhad Announces Datuk Dr. Anis Re-Designated from Chairman/Independent Director to Chairman/Non Independent and Non Executive Director	23-03-20	CI
Y.S.P. Southeast Asia Holding Berhad Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Y.S.P. Southeast Asia Holding Berhad Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-27	CI

Chart Y.S.P. Southeast Asia Holding

Duration

Period

More charts

Company Profile

Y.S.P. Southeast Asia Holding Berhad is a Malaysia-based pharmaceutical company. The Company provides a range of pharmaceutical, over-the-counter (OTC), veterinary and aquatic products. The Company's segments include Manufacturing, Trading and Investment holding. The Manufacturing segment is engaged in the manufacturing of pharmaceutical products. The Trading segment is involved in the import, export and trading of various kinds of pharmaceutical, traditional herbal and veterinary products. The Company is engaged in investment holding and provision of management services. Its subsidiaries include Y.S.P. (Cambodia) Pte. Ltd., which provides management services in respect of product registration, trademark registration and national marketing and trading in all kinds of pharmaceutical products, and Alpha Active Industries Sdn. Bhd., which is engaged in the manufacturing of biotechnology products and health products.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
Y.S.P. SOUTHEAST ASIA HOLDING	+26.09%	87.36M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.40%	42.95B
OTSUKA HOLDINGS CO., LTD.	+15.48%	21.38B
SANDOZ GROUP AG	+18.33%	15.05B
CIPLA LIMITED	+18.78%	14.45B
ZYDUS LIFESCIENCES LIMITED	+54.82%	13.04B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.60%	6.72B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+11.21%	5.47B